ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Department of Health and Human Services (HHS) has informed the company that its proposal to provide a recombinant protective antigen anthrax vaccine (rPA) is technically acceptable and within the competitive range. Emergent’s proposal was in response to HHS’s request for proposal (RFP) for development and delivery of 25 million doses of an rPA anthrax vaccine for the Strategic National Stockpile. As a next step, Emergent will begin to provide additional technical and business information in connection with the ongoing negotiation process.
